Valneva (NASDAQ:VALN) Downgraded by Wall Street Zen to Sell

Valneva (NASDAQ:VALN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other brokerages also recently issued reports on VALN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Valneva in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Valneva in a report on Monday, August 25th. Guggenheim dropped their target price on Valneva from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Monday, September 8th. Finally, Jefferies Financial Group set a $14.00 price objective on shares of Valneva and gave the company a “buy” rating in a report on Monday, August 25th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Valneva Stock Performance

VALN opened at $8.90 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.78 and a quick ratio of 1.36. The business has a fifty day simple moving average of $9.64 and a 200 day simple moving average of $8.35. Valneva has a 1 year low of $3.62 and a 1 year high of $12.25. The company has a market capitalization of $765.22 million, a PE ratio of -6.18 and a beta of 1.83.

Valneva (NASDAQ:VALN) last announced its earnings results on Thursday, November 20th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.31). The business had revenue of $34.01 million for the quarter, compared to the consensus estimate of $48.85 million. Valneva had a negative return on equity of 59.44% and a negative net margin of 57.81%. Research analysts expect that Valneva will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. purchased a new position in shares of Valneva during the second quarter valued at approximately $8,240,000. Marex Group plc purchased a new position in Valneva during the 2nd quarter worth $64,000. JPMorgan Chase & Co. purchased a new position in Valneva during the 3rd quarter worth $124,000. Finally, VSM Wealth Advisory LLC grew its stake in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.